QURE INVESTOR NOTICE: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism, Lawsuit Filed; April 13 Deadline Nears
MWN-AI** Summary
Hagens Berman, a national shareholder rights law firm, has escalated its investigation into uniQure N.V. (NASDAQ: QURE) following significant criticism from the FDA regarding the company’s lead gene therapy candidate, AMT-130. The firm has filed a securities class action lawsuit aimed at representing investors who purchased uniQure shares from September 24 to October 31, 2025. A critical deadline for investors wishing to be appointed as Lead Plaintiff is set for April 13, 2026.
The FDA's rebuke, reported by major media outlets on March 5 and 6, labels AMT-130 a "failed therapy" and accuses uniQure of manipulating comparisons in their clinical studies. An FDA official specifically called out the company's handling of sham surgeries, clarifying that the agency did not request "drill holes in skulls" but rather allowed for minimally invasive procedures. Additionally, the FDA has denied uniQure's claims of prior agreements regarding study designs and dismissed the company’s qualification for any streamlined review pathways under rare disease protocols.
The class action suit "Scocco v. uniQure N.V., et al." alleges that the company misrepresented its conversations with the FDA and failed to disclose crucial information regarding study designs and regulatory agreements. This alleged deception culminated in a significant stock drop of 49% following revelations of the FDA's lack of approval for the study’s methods.
Investors are encouraged to review the allegations on Hagens Berman's dedicated case page, as the firm continues to seek those affected by the events leading to the recent decline in uniQure's stock. Whistleblowers with information relevant to the investigation may consider reaching out to the firm for potential rewards under the SEC Whistleblower program.
MWN-AI** Analysis
In light of the recent developments concerning uniQure N.V. (NASDAQ: QURE), investors are advised to proceed with caution. The company is facing significant scrutiny following critical remarks from FDA officials regarding its lead gene therapy candidate, AMT-130. The FDA labeled AMT-130 a “failed therapy” and challenged uniQure's interpretations of regulatory requirements, which indicates potential regulatory hurdles that could impede the drug's path to market.
The ongoing investigation by Hagens Berman, coupled with the pending securities class action lawsuit, highlights further risks for current and prospective investors. The lawsuit alleges that uniQure misrepresented its interactions with the FDA and failed to disclose critical information related to study design and regulatory consensus. The timing of this litigation, with the April 13, 2026, deadline for investors to appoint a Lead Plaintiff, could exacerbate stock volatility and investor sentiment.
Given the complexities surrounding the litigation and the FDA’s stance, potential investors should critically assess uniQure's financial health and operational transparency. The recent sharp decline in stock price, which dropped 49% following the revelations about regulatory miscommunication, underscores the uncertainty surrounding the company's future.
Investors may want to adopt a more defensive strategy, monitoring the outcome of the lawsuit and any new developments from the FDA before making significant investments in uniQure. Additionally, those who purchased shares during the Class Period are encouraged to consult with legal representatives regarding their options to participate in the ongoing class action.
Overall, while the gene therapy space holds potential, the bumps along uniQure's road appear acute and merit careful observation and analysis. As always, diversifying portfolios and remaining informed on major company announcements is critical in managing investment risk.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SAN FRANCISCO, April 5, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 (the "Class Period"). The firm reminds investors of the April 13, 2026, Lead Plaintiff deadline in the pending securities class action.
SUBMIT YOUR QURE LOSSES TO HBSS NOW
DEEP DIVE ANALYIS: Visit Hagens Berman's dedicated QURE case page: www.hbsslaw.com/cases/uniqure, or view our latest video summary of the allegations: https://youtu.be/VWKl1BzabcE
The FDA Clash: "A Distorted or Manipulated Comparison"
On March 5 and 6, 2026, media outlets including The Wall Street Journal, CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.
The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the mind of FDA" instead of running a correct clinical study.
Key revelations from the March 6 disclosure include:
- Sham Surgery Mischaracterization: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, accusing the company of mischaracterizing the agency's request. The official clarified that the FDA did not ask to "drill holes in skulls," but rather required "one to three nicks in the scalp" under minimal anesthesia.
- Denial of Prior Agreement: While uniQure CEO Matt Kapusta described the sham surgery requirement as a "drastic change" from previous guidance, the FDA official pushed back, stating the agency "never agreed to accept this distorted comparison" using natural history as a comparator.
- Ineligibility for "Plausible Mechanism" Pathway: The official disputed AMT-130's eligibility for streamlined rare-disease pathways, noting it is not an individualized treatment.
The recent reports follow the filing of a securities class action suit.
Investors in uniQure (QURE) are encouraged to visit the Hagens Berman QURE Case Page to review the allegations in the pending litigation: www.hbsslaw.com/cases/uniqure
"The pending securities class action alleges a consistent pattern: that uniQure misrepresented its interactions with the FDA and used a pivotal study design that it knew the agency had not approved," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claim in the pending litigation.
Summary of QURE Class Action Allegations: The "Pivotal" Study Mirage
The securities class action, Scocco v. uniQure N.V., et al. (S.D.N.Y.), alleges that throughout the Class Period (Sept. 24, 2025 – Oct. 31, 2025), defendants failed to disclose:
- No Regulatory Consensus: That the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130.
- Hidden Requirements: That uniQure downplayed the necessity of a sham-controlled surgery arm for Phase III—a requirement the FDA now claims was never waived.
- Timeline Deception: That defendants misled investors regarding the timing of a Biologics License Application (BLA), which was rendered "unclear" once the lack of FDA agreement was revealed on November 3, 2025, sending the stock down 49%.
Critical Deadline: April 13, 2026
If you purchased uniQure ordinary shares during the Class Period (Sept. 24, 2025 – Oct. 31, 2025) and suffered losses, you have until April 13, 2026, to ask the Court to appoint you as Lead Plaintiff.
- Submit Your QURE Losses to HBSS Now
- Contact: Reed Kathrein at 844-916-0895 or email QURE@hbsslaw.com
If you'd like more information and answers to additional frequently asked questions about the uniQure case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding uniQure should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email QURE@hbslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
SOURCE Hagens Berman Sobol Shapiro LLP
FAQ**
What specific misrepresentations is the securities class action alleging uniQure N.V. QURE made regarding its interactions with the FDA and the study design for its gene therapy candidate AMT-130?
How has the FDA’s recent criticism of uniQure N.V. QURE affected investor confidence in the company and its future prospects, particularly in light of the upcoming April 13, 2026, deadline?
What are the potential implications for uniQure N.V. QURE if the court grants the class action suit, and how might this impact the company's valuation moving forward?
Can investors who acquired shares of uniQure N.V. QURE during the specified Class Period still participate in the lawsuit, and what steps should they take to ensure their interests are represented?
**MWN-AI FAQ is based on asking OpenAI questions about uniQure N.V. (NASDAQ: QURE).
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
